company background image
MGTA

Magenta Therapeutics NasdaqGM:MGTA Stock Report

Last Price

US$1.14

Market Cap

US$68.6m

7D

-1.7%

1Y

-79.4%

Updated

01 Dec, 2022

Data

Company Financials +
MGTA fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

MGTA Stock Overview

Magenta Therapeutics, Inc., a clinical-stage biotechnology company, develops medicines to bring the curative power of stem cell transplants to patients with blood cancers, genetic diseases, and autoimmune diseases.

Magenta Therapeutics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Magenta Therapeutics
Historical stock prices
Current Share PriceUS$1.14
52 Week HighUS$5.90
52 Week LowUS$0.92
Beta1.96
1 Month Change-8.07%
3 Month Change-34.10%
1 Year Change-79.38%
3 Year Change-91.22%
5 Year Changen/a
Change since IPO-92.15%

Recent News & Updates

Magenta Therapeutics downgraded to neutral at Goldman Sachs on clarity over candidate

Aug 25

Is Magenta Therapeutics (NASDAQ:MGTA) In A Good Position To Invest In Growth?

Jul 13
Is Magenta Therapeutics (NASDAQ:MGTA) In A Good Position To Invest In Growth?

Recent updates

Is Magenta Therapeutics (NASDAQ:MGTA) In A Good Position To Invest In Growth?

Jul 13
Is Magenta Therapeutics (NASDAQ:MGTA) In A Good Position To Invest In Growth?

Here's Why We're Not Too Worried About Magenta Therapeutics' (NASDAQ:MGTA) Cash Burn Situation

Apr 12
Here's Why We're Not Too Worried About Magenta Therapeutics' (NASDAQ:MGTA) Cash Burn Situation

Here's Why We're Not Too Worried About Magenta Therapeutics' (NASDAQ:MGTA) Cash Burn Situation

Dec 16
Here's Why We're Not Too Worried About Magenta Therapeutics' (NASDAQ:MGTA) Cash Burn Situation

Magenta Therapeutics (NASDAQ:MGTA) Is In A Good Position To Deliver On Growth Plans

Aug 26
Magenta Therapeutics (NASDAQ:MGTA) Is In A Good Position To Deliver On Growth Plans

We're Not Very Worried About Magenta Therapeutics' (NASDAQ:MGTA) Cash Burn Rate

May 09
We're Not Very Worried About Magenta Therapeutics' (NASDAQ:MGTA) Cash Burn Rate

What Kind Of Shareholders Hold The Majority In Magenta Therapeutics, Inc.'s (NASDAQ:MGTA) Shares?

Mar 17
What Kind Of Shareholders Hold The Majority In Magenta Therapeutics, Inc.'s (NASDAQ:MGTA) Shares?

Magenta Therapeutics (NASDAQ:MGTA) Is In A Good Position To Deliver On Growth Plans

Jan 23
Magenta Therapeutics (NASDAQ:MGTA) Is In A Good Position To Deliver On Growth Plans

What Kind Of Shareholders Hold The Majority In Magenta Therapeutics, Inc.'s (NASDAQ:MGTA) Shares?

Dec 01
What Kind Of Shareholders Hold The Majority In Magenta Therapeutics, Inc.'s (NASDAQ:MGTA) Shares?

Shareholder Returns

MGTAUS BiotechsUS Market
7D-1.7%2.7%1.4%
1Y-79.4%-10.3%-16.1%

Return vs Industry: MGTA underperformed the US Biotechs industry which returned -10.2% over the past year.

Return vs Market: MGTA underperformed the US Market which returned -14.8% over the past year.

Price Volatility

Is MGTA's price volatile compared to industry and market?
MGTA volatility
MGTA Average Weekly Movement15.2%
Biotechs Industry Average Movement11.2%
Market Average Movement7.4%
10% most volatile stocks in US Market15.6%
10% least volatile stocks in US Market3.3%

Stable Share Price: MGTA is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 15% a week.

Volatility Over Time: MGTA's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
201566Jason Gardnerhttps://www.magentatx.com

Magenta Therapeutics, Inc., a clinical-stage biotechnology company, develops medicines to bring the curative power of stem cell transplants to patients with blood cancers, genetic diseases, and autoimmune diseases. It develops MGTA-117, an anti-CD117 antibody that targets hematopoietic stem cells (HSCs) and genetically mutated stem cells that cause acute myeloid leukemia and myelodysplastic syndromes, which is under Phase I/II clinical trial; CD45-antibody drug conjugate that targets HSCs and immune cells, which is in investigational new drug application enabling studies for potential use as a single-agent in autoimmune diseases and hematology-oncology transplants; and MGTA-145 that is in Phase II clinical trial for use in autologous and allogeneic transplants. The company also has a cell therapy program, E478, which is a small molecule aryl hydrocarbon receptor antagonist for stem cell-based gene therapy and genome editing.

Magenta Therapeutics, Inc. Fundamentals Summary

How do Magenta Therapeutics's earnings and revenue compare to its market cap?
MGTA fundamental statistics
Market CapUS$68.56m
Earnings (TTM)-US$75.58m
Revenue (TTM)n/a

0.0x

P/S Ratio

-0.9x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
MGTA income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$75.58m
Earnings-US$75.58m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-1.26
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did MGTA perform over the long term?

See historical performance and comparison